Overview

• The investment adds to a prior $3.5 billion U.S. pledge from November 2024, raising total U.S. commitments above $53 billion.
• A flagship Virginia plant will be the company’s largest single manufacturing facility, producing active ingredients for experimental weight-loss and cholesterol medicines.
• Expansion of R&D and cell therapy sites is planned in Maryland, Massachusetts, California, Indiana and Texas to support clinical trials and novel treatments.
• The move aligns with a Section 232 investigation that could impose up to 200 percent tariffs on imported drugs under President Trump’s trade policies.
• AstraZeneca forecasts that the projects will create tens of thousands of new high-skilled jobs across its U.S. network.